Skip to main content
. 2020 Jun;9(3):1252–1261. doi: 10.21037/tau-19-755

Table 4. Comparison of clinical and MRI data of transitional lesions.

Clinical and MRI data Non-clinically significant cancer (n=63) Clinically significant cancer (n=4)
Age (years), mean [SD] 73 [9] 73 [8]
tPSA (ng/mL), median (IQR) 10.03 (5.20–17.28) 45.07 (17.19–60.85)
fPSA (ng/mL), median (IQR) 1.57 (0.80–2.39) 4.45 (2.18–6.37)
f/tPSA, median (IQR) 0.17 (0.11–0.22) 0.12 (0.08–0.21)
PSAD (ng/mL2), median (IQR) 0.17 (0.11–0.31) 0.47 (0.21–0.78)
PV (mL), median (IQR) 50.00 (35.00–69.90) 81.71 (53.88–126.75)
Lesion diameter (mm), mean (SD) 19.47 (3.87) 16.64 (1.74)
Lesion location, n (%)
   Base 20 (31.7) 0
   Middle 31 (49.2) 1 (25.0)
   Apex 12 (19.0) 3 (75.0)

MRI, magnetic resonance imaging; SD, standard deviation; IQR, interquartile range; tPSA, total prostate-specific antigen; fPSA, free PSA; f/tPSA, ratio of free-to-total PSA; PSAD, PSA density; PV, prostate volume.